Table 1.
Clinical data, aCTCs and aCTCs subsets status (negative vs. positive cut-off), and survival data (PFS and OS).
| Patients’ Characteristics | N (%) | |
|---|---|---|
| Age at inclusion, years | 55 (27–79) | |
| Metastasis to diagnosis interval, years | 3 (0.59–23) | |
| Pathological type of primary tumor | ductal | 75 (93%) |
| lobular | 6 (7%) | |
| missing | 10 | |
| Pathological grade of primary | 1 | 5 (7%) |
| 2 | 32 (43%) | |
| 3 | 37 (50%) | |
| missing | 17 | |
| Molecular subtype of primary tumor | HR+/HER2− | 50 (56%) |
| HER2+ | 11 (12%) | |
| TN | 29 (32%) | |
| missing | 1 | |
| Molecular subtype of metastasis | HR+/HER2− | 36 (41%) |
| HER2+ | 11 (13%) | |
| TN | 40 (46%) | |
| missing | 4 | |
| Bone metastasis | no | 32 (35%) |
| yes | 59 (65%) | |
| Liver metastasis | no | 39 (43%) |
| yes | 52 (57%) | |
| Lung-pleural metastasis | no | 45 (49%) |
| yes | 46 (51%) | |
| Brain-meningeal metastasis | no | 81 (89%) |
| yes | 10 (11%) | |
| Lymph node metastasis | no | 34 (37%) |
| yes | 57 (63%) | |
| Skin metastasis | no | 73 (80%) |
| yes | 18 (20%) | |
| Peritoneum metastasis | no | 81 (89%) |
| yes | 10 (11%) | |
| Other metastatic site | no | 66 (73%) |
| yes | 25 (27%) | |
| Number of metastasic sites at inclusion, N | 3 (1–8) | |
| Number of previous lines of systemic therapy at inclusion, N | 4 (1–10) | |
| Atypical circulating cells (all subsets) | Negative | 35 (38%) |
| Positive | 56 (62%) | |
| s-aCTC | Negative | 42 (46%) |
| Positive | 49 (54%) | |
| CTM | Negative | 44 (48%) |
| Positive | 47 (52%) | |
| g-aCTC | Negative | 49 (54%) |
| Positive | 42 (46%) | |
| Follow-up median, months (range) | 12 (1–52) | |
| PFS events, N (%) | 90 (99%) | |
| Median PFS, months (min–max) | 5 (1–47) | |
| 1-year PFS, % [95% CI] | 13% (8–22) | |
| OS events, N (%) | 68 (75%) | |
| Median OS, months (min-max) | 14 (1–52) | |
| 1-year OS, % [95% CI] | 58% (49–70) | |